written on 23.06.2014

The Luxury of Uncertainty


Biosimilar competition continues to trend as a significant topic in the pharmaceutical industry for many reasons. First, the biologic products targeted for competition over the next five years rank among some of the highest grossing franchises globally, including Humira, Enbrel, Rituxan, Remicade and Herceptin. With each target driving between $1B-$5B in US dose sales alone, […]